These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 10404337)

  • 41. In vitro pharmacodynamic activities of ABT-492, a novel quinolone, compared to those of levofloxacin against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.
    Gunderson SM; Hayes RA; Quinn JP; Danziger LH
    Antimicrob Agents Chemother; 2004 Jan; 48(1):203-8. PubMed ID: 14693540
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Susceptibility testing interpretive criteria for levofloxacin when testing respiratory pathogens, Haemophilus influenzae and Moraxella catarrhalis.
    Cormican MG; Erwin ME; Marshall SA; Jones RN
    Diagn Microbiol Infect Dis; 1996 Mar; 24(3):155-60. PubMed ID: 8724401
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Anti-pneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents.
    Hoellman DB; Lin G; Jacobs MR; Appelbaum PC
    J Antimicrob Chemother; 1999 May; 43(5):645-9. PubMed ID: 10382885
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative in vitro activity of three fluoroquinolones against clinical isolates by E test.
    Madhusudhan KT; Counts C; Lody C; Carter O; Dodson S; Ojha N
    Chemotherapy; 2003 Jul; 49(4):184-8. PubMed ID: 12886053
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin.
    Gilbert DN; Kohlhepp SJ; Slama KA; Grunkemeier G; Lewis G; Dworkin RJ; Slaughter SE; Leggett JE
    Antimicrob Agents Chemother; 2001 Mar; 45(3):883-92. PubMed ID: 11181375
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A comparison of the activity of ciprofloxacin and levofloxacin with other agents against respiratory tract pathogens.
    Wise R; Andrews JM
    J Chemother; 1998 Aug; 10(4):276-9. PubMed ID: 9720464
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vitro activity of levofloxacin against gram-positive bacteria.
    Montanari MP; Mingoia M; Marchetti F; Varaldo PE
    Chemotherapy; 1999; 45(6):411-7. PubMed ID: 10567771
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens.
    Hansen GT; Blondeau JM
    J Chemother; 2005 Oct; 17(5):484-92. PubMed ID: 16323436
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tentative criteria for confirming the in vitro susceptibilities of Haemophilus influenzae and Neisseria gonorrhoeae to two fluoroquinolones (sparfloxacin and levofloxacin), including quality control parameters.
    Barry AL; Fuchs PC; Allen SD; Jorgensen JH; Tenover FC; Murray PR; Hardy DJ; Baker CN
    J Clin Microbiol; 1993 Sep; 31(9):2375-80. PubMed ID: 8408559
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Current status of resistance of bacteria to pefloxacin in hospital units. Cross resistance with ofloxacin and ciprofloxacin. Results of a multicenter study].
    Thabaut A; Meyran M; Fabre R; Dellamonica P; Moreau N
    Pathol Biol (Paris); 1994 May; 42(5):369-74. PubMed ID: 7824298
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vitro antibacterial activity of ceftobiprole against clinical isolates from French teaching hospitals: proposition of zone diameter breakpoints.
    Lascols C; Legrand P; Mérens A; Leclercq R; Muller-Serieys C; Drugeon HB; Kitzis MD; Reverdy ME; Roussel-Delvallez M; Moubareck C; Brémont S; Miara A; Gjoklaj M; Soussy CJ
    Int J Antimicrob Agents; 2011 Mar; 37(3):235-9. PubMed ID: 21295447
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.
    Mushtaq S; Warner M; Ge Y; Kaniga K; Livermore DM
    J Antimicrob Chemother; 2007 Aug; 60(2):300-11. PubMed ID: 17548456
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The susceptibility of Streptococcus pneumoniae to levofloxacin and other antibiotics.
    Keller N; Smollen G; Davidson Y; Barzilai A; Keren G; Rubinstein E
    J Antimicrob Chemother; 1999 Jun; 43 Suppl C():1-3. PubMed ID: 10404329
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vitro activity of the new 4-quinolone compound Ro 23-6240.
    Clarke AM; Zemcov SJ
    Eur J Clin Microbiol; 1987 Apr; 6(2):161-4. PubMed ID: 3109895
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vitro susceptibilities of bacterial ocular isolates to fluoroquinolones.
    Graves A; Henry M; O'Brien TP; Hwang DG; Van Buskirk A; Trousdale MD
    Cornea; 2001 Apr; 20(3):301-5. PubMed ID: 11322420
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [In vitro antibacterial activity of 2 new quinolones: A 56619 (difloxacin) and A 56620. Comparison with pefloxacin, ofloxacin and ciprofloxacin].
    Soussy CJ; Deforges L; Le Van Thoi J; Duval J
    Pathol Biol (Paris); 1987 Jun; 35(5 Pt 2):759-67. PubMed ID: 3309811
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The North American component (the United States and Canada) of an International Comparative MIC trial monitoring ofloxacin resistance.
    Hoban DJ; Jones RN; Harrell LJ; Knudson M; Sewell D
    Diagn Microbiol Infect Dis; 1993; 17(2):157-61. PubMed ID: 8243037
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Activity of levofloxacin and ciprofloxacin against urinary pathogens.
    Drago L; De Vecchi E; Mombelli B; Nicola L; Valli M; Gismondo MR
    J Antimicrob Chemother; 2001 Jul; 48(1):37-45. PubMed ID: 11418511
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fluoroquinolone susceptibility testing of Salmonella enterica: detection of acquired resistance and selection of zone diameter breakpoints for levofloxacin and ofloxacin.
    Sjölund-Karlsson M; Howie RL; Crump JA; Whichard JM
    J Clin Microbiol; 2014 Mar; 52(3):877-84. PubMed ID: 24391204
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vitro activity of enoxacin versus ciprofloxacin, fleroxacin, lomefloxacin, ofloxacin, pefloxacin, and rufloxacin against uropathogens.
    Naber KG; Well M; Hollauer K; Kirchbauer D; Witte W
    Chemotherapy; 1998; 44(2):77-84. PubMed ID: 9551236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.